-
Albany Molecular Research Reports Mixed Results (AMRI)
Monday, February 7, 2011 - 8:12am | 260Albany, New York-based Albany Molecular Research, Inc. (Nasdaq: AMRI) released financial results on Monday morning that missed Wall Street earnings estimates, while beating revenue expectations. Albany Molecular Research, Inc announced that its 4th quarter net loss widened to $49.1 million, or $1....
-
UBS Price Target Research Summary
Friday, February 4, 2011 - 11:31am | 231UBS is out with a research report this morning regarding its Ratings and Price Target changes. In the report, UBS lowered its AutoNation (NYSE: AN) price target to $27 from $20, lowered its CVS Caremark (NYSE: CVS) price target to $42 from $46, raised Diamond Offshore Drilling's (NYSE: DO) price...
-
pSivida Announces Positive Results from the 36 Month Readout of Completed Phase 3 FAME
Thursday, February 3, 2011 - 5:26pm | 29pSivida Corp. (NASDAQ: PSDV) today announced month 36, top-line readout results for the FAME Study prepared by its licensee, Alimera Sciences, Inc..
-
AMRI Receives AIFA Approval to Manufacture Commercial Drug Product in EU
Thursday, February 3, 2011 - 3:00pm | 109AMRI (NASDAQ: AMRI) announced today that it has received approval from the Italian Medicines Agency for its facility in Burlington, MA to manufacture the commercial drug product octreotide for a customer in the European Union. This approval was subject to the successful completion of an AIFA audit...
-
Calls Purchased on Medivation, Inc. (MDVN)
Thursday, February 3, 2011 - 1:53pm | 122Shares of Medivation, Inc. (NASDAQ: MDVN) are higher on the session by 0.27%, currently trading at $14.64. The stock has been moving largely higher over the past four months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying calls on the name today. A...
-
Affymetrix Net Soars, Sales Dip - Analyst Blog
Thursday, February 3, 2011 - 11:07am | 973California-based genetic products maker Affymetrix Inc's (AFFX) fourth-quarter fiscal 2010 adjusted (excluding one-time items) earnings per share of 5 cents were ahead of the Zacks Consensus Estimate of 3 cents and the year-ago earnings of 4 cents per share. Profit for the quarter cruised 42%...
-
Affymetrix Net Soars, Sales Dip - Analyst Blog
Thursday, February 3, 2011 - 10:45am | 973California-based genetic products maker Affymetrix Inc's (AFFX) fourth-quarter fiscal 2010 adjusted (excluding one-time items) earnings per share of 5 cents were ahead of the Zacks Consensus Estimate of 3 cents and the year-ago earnings of 4 cents per share. Profit for the quarter cruised 42%...
-
Piper Jaffray Maintains Illumina Overweight Rating (ILMN)
Thursday, February 3, 2011 - 9:49am | 149Piper Jaffray maintained its Illumina (NASDAQ: ILMN) Overweight rating in a research report published today. Piper Jaffray stated that its Illumina $61 pirce target will be under review following Illumina's Q4 2010 earnings release and conference call. In the report, Piper Jaffray states, "Initial...
-
Piper Jaffray Maintains Illumina Overweight Rating (ILMN)
Thursday, February 3, 2011 - 9:49am | 149Piper Jaffray maintained its Illumina (NASDAQ: ILMN) Overweight rating in a research report published today. Piper Jaffray stated that its Illumina $61 pirce target will be under review following Illumina's Q4 2010 earnings release and conference call. In the report, Piper Jaffray states, "Initial...
-
Societe Generale Ups QGEN To Buy
Thursday, February 3, 2011 - 6:54am | 40Analysts at Societe Generale upgrade Qiagen NV (NASDAQ: QGEN) from “hold” to “buy.” QGEN shares fell 1.94% to close at $18.15 yesterday. More Analyst Ratings here
-
Thermo Fisher Beats & Meets - Analyst Blog
Wednesday, February 2, 2011 - 6:21pm | 594Thermo Fisher Scientific (TMO) reported an EPS of 75 cents in the fourth quarter of fiscal 2010 compared to 65 cents in the year-ago period. However, after adjusting for certain one-time items, the EPS was $1.00, surpassing the Zacks Consensus Estimate of 95 cents and 10% higher than 91 cents of...
-
Thermo Fisher Beats & Meets - Analyst Blog
Wednesday, February 2, 2011 - 5:42pm | 594Thermo Fisher Scientific (TMO) reported an EPS of 75 cents in the fourth quarter of fiscal 2010 compared to 65 cents in the year-ago period. However, after adjusting for certain one-time items, the EPS was $1.00, surpassing the Zacks Consensus Estimate of 95 cents and 10% higher than 91 cents of...
-
Affymetrix Reports Q4 EPS of $.06 vs. $.03
Wednesday, February 2, 2011 - 5:02pm | 157Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results for the fourth quarter and fiscal year ended December 31, 2010. Total revenue for the fourth quarter was $84.9 million, as compared to total revenue of $88.8 million in the fourth quarter of 2009. For the full year 2010, total...
-
Deutsche Bank Reiterates Buy Rating on Thermo Fisher (TMO)
Wednesday, February 2, 2011 - 1:50pm | 127Deutsche Bank is out with a research report this afternoon, where it reiterates its Buy rating on Thermo Fisher (NYSE: TMO). The DB analysts cited the company's recent earnings report, noting: 1. “EPS well above Street despite top-line headwinds, driven by margin expansion and tax rate/buyback...
-
Setback for Orexigen - Analyst Blog
Wednesday, February 2, 2011 - 10:52am | 696Orexigen Therapeutics Inc. (OREX) was dealt a severe blow by the US Food and Drug Administration (FDA) when the regulatory body declined to approve its obesity drug, Contrave in the present form and issued a complete response letter (CRL). Contrave, which aimed at addressing the physiological and...